LeMaitre acquires endograft maker
This article was originally published in The Gray Sheet
Executive Summary
EndoMed will maintain its Phoenix manufacturing facilities for the time being, but will relocate corporate business to LeMaitre Vascular's Burlington, Mass. headquarters. The privately held vascular company completed the EndoMed purchase for an undisclosed price Feb. 2. EndoMed is in Phase I clinical trials to gain premarket approval for its Endofit endovascular stent graft, CE-marked in Europe. Last April, LeMaitre began a trial to support U.S. approval of its Expedial vascular access graft, acquired a year earlier from Credent Vascular Technologies. The randomized study - initially aiming to enroll 172 patients - has progressed more slowly than expected, LeMaitre says...
You may also be interested in...
LeMaitre Vascular Tabs Part Of IPO Proceeds For AAA Stent Graft Trial
LeMaitre Vascular is awaiting final FDA go-ahead for a pivotal trial of its EndoFit AUI "aorto-uni-iliac" endovascular stent graft to treat abdominal aortic aneurysms, the company says
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.